Retraction: MNK1-Induced eIF-4E Phosphorylation in Myeloma Cells: A Pathway Mediating IL-6-Induced Expansion and Expression of Genes Involved in Metabolic and Proteotoxic Responses (PLoS ONE (2014) 9:4 (e94011) DOI: 10.1371/journal.pone.0094011);MNK1-induced eIF-4E phosphorylation in myeloma cells: A pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Shi, Yijiang ^a,b   Frost, Patrick ^a,b   Hoang, Bao ^a,b   Yang, Yonghui ^a,b   Bardeleben, Carolyne ^a,b   Gera, Joseph ^a,b   Lichtenstein, Alan ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 3 (4 FLUOROPHENYLAMINO)PYRAZOLO(3,4D)PYRIMIDINE; CGP 57380; IMMUNOGLOBULIN G; INITIATION FACTOR 4E; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 1; PYRIMIDINE DERIVATIVE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; MKNK1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; RIBOSOME; RNA TRANSLATION; TUMOR XENOGRAFT; ANIMAL; METABOLISM; PHOSPHORYLATION; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84899577519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0291491     Document Type: Erratum

References (42)

1. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB (2004) Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci 101:18105-18110. (Pubitemid 40054081)
2. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, et al. (2004) MNK2 and MNK1 are essential for constitutive and inducible phosphorylation of eIF-4E but not for cell growth or development. Mol. Cell Biol. 24: 6539-6549. (Pubitemid 38944335)
3. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes & Dev 21:3232-3237. (Pubitemid 350277750)
4. Furic L, Rong L, Larsson O, Koumakpayi I, Yoshida K, et al. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci 107:14134-14139.
5. Ueda T, Sasaki M, Elia AL, Chio I, Hamada K, et al. (2010) Combined deficiency for MAP kinase-interacting kinase 1 and 2 (MNK 1 and MNK 2) delays tumor development. Proc Natl Acad Sci 107:13984-13990.
6. Pellagatti A, Vetrie D, Langford CD, Gama S, Eagleton H, et al. (2003) Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res 63:3940-3944. (Pubitemid 36917909)
7. Worch J, Tickenbrock L, Schwable J, Steffen B, Cauvet T, et al. (2004) The serine-threonine kinase MNK1 is post-transationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells. Oncogene 23:9162-9172. (Pubitemid 40069686)
8. Bredel M, Bredel C, Juric D (2005) High resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res 65:4088-4096. (Pubitemid 40775645)
9. Fan S, Ramalingham SS, Kauh J, Xu Z, Khuri FR, et al. (2009) Phosphorylated eIF4E is elevated in human cancer tissues. Cancer Biol Ther 8:1463-1469.
10. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, et al. (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathwy in non-small cell lung cancer. Clin Cancer Res 16:240-248.
11. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 59cap. Nature 345:544-547.
12. Topisirovic I, Ruiz-Gutierrez M, Borden KL (2004) Phosphorylation of the eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64:8639-8642. (Pubitemid 39552077)
13. Ogata A, Chauhan D, Teoh G, Treon S, Urashima M, et al. (19997) IL-6 triggers cell growth via the RAS-dependent mitogen-activated protein kinase cascade. J Immunol 159:2212-2221.
14. Fukunaga R, Hunter T (1997) MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 16:1921-1997.
15. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116: 4560-4568.
16. Sharma S, Nemeth E, Chen Y, Goodnough J, Huston A, et al. (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14:3262-3267.
17. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA (1997) Mitogen-activated protein kinases activate the serine/threonine kinses MNK1 and MNK2. EMBO J 16:1909-1920. (Pubitemid 27170952)
18. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, et al. (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104(13):4181-87. (Pubitemid 39620172)
19. Lock R, Roy S, Kenific C (2011) Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol of the Cell 22:165-178.
20. Ingolia N, Ghaemmaghami S, Newman J, Weissman J (2009) Genome wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324:218-223.
21. Thoreen C, Chantranupong L, Keys H, Wang T, Gray N, et al. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485:109-113.
22. Jernberg-Wiklund H, Pettersson M, Carlsson M, Nilsson K (1992) Increase in IL-6 and IL-6 receptor expression in a human multiple myeloma cell line, U- 266, during long term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 6:310-318.
23. Parra JL, Buxade M, Proud CG (2005) Features of the catalytic domains and C termini of the MAPK signal-integrating kinases MNK1 and MNK2 determine their differing activities and regulatory properties. J. Biol. Chem. 280: 37623-37633. (Pubitemid 41642371)
24. Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B (1995) Introduction of an activated N-ras oncogene alters the growth characteristics of the IL-6-dependent myeloma cell line ANBL6. Cancer Res 55:3640-3646.
25. Knauf U, Tschopp C, Gram H (2001) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol cell Biol 21:5500-5511. (Pubitemid 32702454)
26. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, et al. (2005) The MNKs are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 23:177-189. (Pubitemid 41169287)
27. Bain J, Plater L, Elliot M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315.
28. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, et al. (2011) Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 71: 1849-57.
29. Shi Y, Frost PJ, Hoang B, Gera J:Lichtenstein A (2008) IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc IRES function and the RNA-binding protein hnRNP A1. Cancer Res 68: 10215-10222.
30. Hsieh A, Liu Y, Edlind M, Ingoloa N, Janes M, et al. (2012) The translational landscape of mTOR signaling steers cancer initiation and metastasis. Nature 485:55-61.
31. Munshi N, Hideshima T, Carrasco D, Shammas M, Auclair D, et al. (2004) Identification of genes modulated in multiple myeloma using genetically identical twin samples. BLOOD 103:1799-1806. (Pubitemid 38268976)
32. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, EnoS M, et al. (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11:349-360. (Pubitemid 46518314)
33. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. BLOOD 107:4907-4916. (Pubitemid 43882644)
34. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, et al. (2005) ARK5 is transcriptionally regulated by the large MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of multiple myeloma. Oncogene 24:6936-6944. (Pubitemid 41509416)
35. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang S, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873-886.
36. Liu L, Ulbrich J, Muller J, Wustfeld T, Aeberhard L, et al. (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012; 483:608-612.
37. Clendening J, pandyra A, Li Z, Boutros P, Martirosyan A, et al. (2010) Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. BLOOD 115:4787-4797.
38. Tirado-Velez JM, Joumady I, Saez-Benito, Cozar-Castellano I, Perdomo G (2012) Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One 7:e46484.
39. Wen XY, Stewart A, Sooknanan RR (1999) Identification of c-myc promoter-binding protein and XBP-1 as interleukin-6 target genes in human myeloma cells. Int J Oncol 15:173-178.
40. Paulin FE, West MJ, Sullivan NF, Whitney RL, Lyne L, et al. (1996) Aberrant translational control of the c-myc gene in multiple myeloma. Oncogene 13:505-513. (Pubitemid 26283847)
41. Frost P, Shi Y, Hoang B, Lichtenstein A (2007) AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26:2255-2262. (Pubitemid 46572812)
42. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, et al. (2009) Molecular targeting of the oncogenic eIF-4E in AML: A proof of principle clinical trial with ribavirin. BLOOD 114:257-260.